Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
Jaecheol KangWoo Hyung LeeJaehoon ShinYejong ParkJae Woo KwonEunsung JunKi Byung SongJae Hoon LeeDae Wook HwangSeo Young ParkSong Cheol KimPublished in: Langenbeck's archives of surgery (2022)
Patients who received adjuvant chemotherapy based on 5-FU/LV showed comparable oncologic outcomes to patients in the OB group even after stratification by tumor stage. The patients with intestinal subtype showed oncologic benefit for adjuvant 5-FU/LV CTx compared with pancreatobiliary or mixed subtypes.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rectal cancer
- early stage
- radical prostatectomy
- peritoneal dialysis
- prognostic factors
- robot assisted
- prostate cancer
- type diabetes
- skeletal muscle
- squamous cell
- patient reported outcomes
- adipose tissue
- multidrug resistant
- young adults
- patient reported
- lymph node metastasis